Recent News

• 06.09.2025 - Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology
• 06.03.2025 - Nutriband CEO Gareth Sheridan to Join Fireside Chat at Noble Capital’s Emerging Growth Conference
• 06.02.2025 - Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl
• 04.30.2025 - CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and milestones through 2024
• 04.17.2025 - Shortlist for 2025 EY Entrepreneur of the Year awards revealed
• 04.04.2025 - Nutriband Inc. Signs Associate Partnership Agreement with Charlotte FC
• 02.13.2025 - Nutriband and Kindeva formalize exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments
• 02.11.2025 - Nutriband Inc. Announces Olympian Anastasia Nichita to Advisory Board
• 02.07.2025 - Nutriband Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversa(TM)

Recent Filings

• 05.30.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.13.2025 - 10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]
• 04.28.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 04.09.2025 - 8-K Current report
• 04.09.2025 - EX-99.1 EX-99.1
• 03.13.2025 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
• 03.13.2025 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
• 02.13.2025 - 8-K Current report
• 02.13.2025 - EX-99.1 EX-99.1
• 02.12.2025 - 8-K Current report